Monash University scientists have identified a potential new drug target to alleviate neuroinflammation, which is reported in ...

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments. The proof-of-concept study introduced a ...

Researchers say GlycoCaging may offer a route to rescue promising drug candidates that currently show unacceptable systemic ...

Learn how AI in drug discovery is revolutionizing therapeutic development and addressing challenges in cell and gene therapy.

Explore the evolving landscape of clinical trials in drug discovery and learn about recent breakthroughs transforming the ...

DynamiQ features an expanded data lakehouse infrastructure, developed in collaboration with Sapient's partner Rancho Biosciences, that enables rapid curation of Sapient's unique datasets comprising ...

Neurological disorders, including Alzheimer’s, Parkinson’s, ALS, and multiple sclerosis, pose significant challenges due to their complex pathophysiology ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems ...

While significant progress has been made in developing treatments for rare diseases—highlighted by the approval of over 800 drugs for orphan diseases since ...